Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1231-1240 of 1,421) with videos related to

Pageof 143
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
Calcified Tissue International|December 6, 2018
Trauma-Induced Nanohydroxyapatite Deposition in Skeletal Muscle is Sufficient to Drive Heterotopic OssificationStephanie N Moore-Lotridge, Qiaoli Li, Breanne H Y Gibson, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Gynecologic Oncology|June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancerKathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Prostate Cancer and Prostatic Diseases|July 23, 2021
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancerMiguel Gonzalez Velez, Heidi E Kosiorek, Jan B Egan, et al.
Journal of Pediatric Orthopedics|October 10, 2018
C-Reactive Protein Predicts Risk of Venous Thromboembolism in Pediatric Musculoskeletal InfectionEmilie Amaro, Tanya K Marvi, Samuel L Posey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
Neurology|November 23, 2005
Seizure focus affects regional language networks assessed by fMRIM M Berl, L M Balsamo, B Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 143

Showing results (1231-1240 of 1,421) with videos related to

Sort By:
Pageof 143
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
Calcified Tissue International|December 6, 2018
Trauma-Induced Nanohydroxyapatite Deposition in Skeletal Muscle is Sufficient to Drive Heterotopic OssificationStephanie N Moore-Lotridge, Qiaoli Li, Breanne H Y Gibson, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Gynecologic Oncology|June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancerKathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Prostate Cancer and Prostatic Diseases|July 23, 2021
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancerMiguel Gonzalez Velez, Heidi E Kosiorek, Jan B Egan, et al.
Journal of Pediatric Orthopedics|October 10, 2018
C-Reactive Protein Predicts Risk of Venous Thromboembolism in Pediatric Musculoskeletal InfectionEmilie Amaro, Tanya K Marvi, Samuel L Posey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
Neurology|November 23, 2005
Seizure focus affects regional language networks assessed by fMRIM M Berl, L M Balsamo, B Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 143